Roth Capital Maintains Buy On Applied Genetic On The Back Of FY14 Results
In a research report issued today, Roth Capital analyst Joseph Pantginis maintained a Buy rating on Applied Genetic Technologies (NASDAQ:AGTC) with a price target of $25, following fiscal year 2014 results, posting EPS of ($4.46) and revenue of $1.129 million.
Pantginis noted, “We believe the company is on track, with clinical programs in both XLRS and ACHM to begin in 2015 based on the company’s proprietary AAV platform. We believe answers could come fast — within three to six months following a single administration of the gene therapy.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Joseph Pantginis has a total average return of -9.7% and a 30.6% success rate. Pantginis has a 39.7% average return when recommending AGTC, and is ranked #3304 out of 3313 analysts.